Dr Reddy’s Laboratories: Q2 FY27 date, Q1 profit dip

Key dates investors are tracking

Dr Reddy’s Laboratories has scheduled a Board meeting on October 23, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026. The company has also indicated an earnings call on October 23 at 7:30 pm, based on the shared schedule details. For context, the company had announced its Q1 FY27 results on July 22, 2026, along with an earnings call at 19:30 IST. These dates matter because they anchor when updated financials and management commentary become available to the market. For investors, the Q2 event will help assess whether Q1 pressures were one-off or continue into the next quarter. The announcement was made through a stock exchange intimation to BSE, as referenced in the provided information.

What the company reported for Q1 FY27

On July 22, 2026, Dr Reddy’s announced consolidated financial results for the quarter ended June 30, 2026 under IFRS. The company reported Q1 FY27 revenue of ₹80,705 million, which normalises to ₹8,070.5 crore. It reported that revenue was down 5.6% year-on-year and up 7.4% quarter-on-quarter. Gross margin was reported at 46.5%. EBITDA for the quarter was ₹10,088 million, or ₹1,008.8 crore, with an EBITDA margin of 12.5% of revenues. Profit before tax was ₹5,526 million, or ₹552.6 crore, as per the same release.

Profit line and semaglutide provision

The company reported profit after tax attributable to equity holders of ₹4,435 million, which is ₹443.5 crore, with diluted EPS of ₹5.32. The same set of disclosures also referenced a semaglutide provision of ₹2,397 million, equivalent to ₹239.7 crore. Separately, the provided material also contained a summary line stating Dr Reddy’s Laboratories reported a net profit of Rs 434, and another headline referencing net profit at ₹443 crore. These figures broadly point to a Q1 profit figure in the ₹434-₹443 crore range depending on the source and rounding, while the exchange-linked Q1 announcement explicitly states profit to equity holders at ₹443.5 crore. Another note in the supplied text attributed a sharp earnings decline to a one-time semaglutide provision and the end of a lenalidomide agreement, while retaining FY27 guidance.

Broker comparison: Motilal Oswal’s estimate vs reported

A broker note in the provided text stated Dr Reddy’s reported 1QFY27 revenue of Rs 80.9 billion, or ₹8,090 crore, and described it as down 5.4% year-on-year after adjusting for a Semaglutide-related impact. The same note said revenue was broadly in line with Motilal Oswal’s estimate of Rs 82.3 billion, which normalises to ₹8,230 crore. The broker table also included EBITDA of Rs 10.9 billion (₹1,090 crore), EBITDA margin of 13.5%, and adjusted PAT of Rs 6.5 billion (₹650 crore), along with year-on-year changes. These figures are presented in the material as part of the broker’s comparison set, and they sit alongside the company’s exchange-linked IFRS metrics that cite EBITDA at ₹1,008.8 crore and profit to equity holders at ₹443.5 crore. Readers should note these are not identical line items, since “adjusted PAT” in broker models can differ from reported PAT attributable to equity holders.

Segment performance: India stood out

Within segment performance highlights, the supplied text stated that India revenue grew 17% to Rs 17.2 billion in Q1 FY27, which normalises to ₹1,720 crore. The note attributed the India growth to innovative and acquired brands, price increases, and volumes. It also stated that seven new brands and oral Semaglutide were launched. Another disclosure line added that Q1FY27 India revenues at ₹17.2 billion accounted for 21% of consolidated revenues, and that the segment grew 17% year-on-year and 10% quarter-on-quarter. This is one of the clearer growth datapoints included in the provided material, even as consolidated revenue was indicated as lower year-on-year.

Filings and governance: dual reporting to investors

The supplied text stated that on July 22, 2026, Dr Reddy’s disclosed its Board had approved unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. It also said the company furnished these Q1 FY2027 numbers to investors and the U.S. SEC via Form 6-K. The note added that the filings were prepared under both IFRS and Indian Accounting Standards, and included limited review reports from statutory auditors. The same set of exchange-linked points also mentioned an appointment: Dr. Sridevi Khambhampaty as Global Head of Biologics. It also referenced Deloitte as auditor, as stated in the provided announcement summary.

Product and regulatory updates in focus

Beyond quarterly numbers, the provided text included regulatory and product updates. Dr Reddy’s said it received DCGI approval for Zytorvi (toripalimab) for first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma in India. The indication described in the release was in combination with cisplatin and paclitaxel. Separately, the material also stated Dr. Reddy's launched India’s first DCGI-approved generic semaglutide injection, Obeda, for Type 2 diabetes management. While these updates do not quantify revenue impact in the shared text, they matter because they reflect portfolio actions that investors often track alongside quarterly performance.

Key reported numbers at a glance

What to watch on October 23

The October 23 Board meeting agenda, as stated, is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The scheduled earnings call the same evening is likely to provide management’s framing of the quarter and the drivers behind the reported numbers. Given that the provided text highlights a semaglutide provision in Q1 and references the end of a lenalidomide agreement as part of the earnings decline narrative, investors will closely read how much of Q1’s impact was non-recurring. India’s reported 17% revenue growth and launches including oral semaglutide and new brands are also likely to remain a tracked datapoint. Any additional details on product launches such as Obeda and the DCGI approval for Zytorvi could be discussed alongside financial results, depending on what the company includes in its disclosures.

Conclusion

Dr Reddy’s has set October 23, 2026 as the key date for Q2 FY27 results, after reporting Q1 FY27 consolidated revenue of ₹8,070.5 crore and PAT attributable to equity holders of ₹443.5 crore, alongside a ₹239.7 crore semaglutide provision. The upcoming Board meeting and earnings call will provide the next set of official numbers for the quarter ended September 30, 2026 and updated management commentary.